Cullinan Therapeutics, Inc.

CGEM Healthcare Biotechnology

In the quarter to June 2026, EPS grew 24.3% and free cash flow grew 33.7%, each against the same quarter a year earlier.

12.93 1.07 −7.64%
Market cap
$901.0M
P/E
0.0×
Fwd P/E
4.8×
Dividend yield
—
F-score
n/a
Altman Z
33.57
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.42 10.28 10.25 10.45
Net Debt/EBITDA
5.85 6.56 6.85 5.99
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.62) (0.76) (0.65) (0.62)
Book value per Share
5.23 6.06 6.92 7.64
Free Cash Flow
(38.22) (46.04) (38.12) (36.91)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates